News

CardioGenics Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap

MISSISSAUGA, Ontario - November 4, 2015 -CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it, and its newly created Canadian subsidiary, have entered into a definitive asset purchase agreement to acquire substantially all of the assets of Plasticap. CardioGenics previously announced on October 5, 2015 that it had entered into a binding letter of intent to acquire substantially all of Plasticap's assets.
read more

CardioGenics Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap

MISSISSAUGA, Ontario - October 5, 2015 -CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it has entered into a binding letter of intent to acquire substantially all of the assets of Plasticap ("LOI"). CardioGenics previously announced on August 25, 2015 that it had entered into a manufacturing agreement with Plasticap, pursuant to which Plasticap will manufacture CardioGenics' proprietary self-metering cartridges for its QL Care™ analyzer.
read more

CardioGenics Enters Into Manufacturing Agreement With Ontario-Based Plasticap

MISSISSAUGA, Ontario - August 25, 2015 -CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics' proprietary self-metering cartridges for its QL Care™ analyzer. The term of the agreement is 3 years and the purchase price for each cartridge shall be as specified in each purchase order issued pursuant to the agreement.
read more

USPTO Issues Notice of Allowance in Connection With CardioGenics' Self-Metering Cartridge Patent Application

MISSISSAUGA, Ontario - February 17, 2015 -CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD") testing market, announced today that the United States Patent & Trademark Office ("USPTO") has issued a Notice of Allowance with respect to certain patent claims contained in its patent application for the self-metering cartridge to be utilized in the Company's QL Care(TM) analyzer. The Notice of Allowance, which is the USPTO's notice to the Company that the allowed patent claims are entitled to patent protection, now clears the way for the issuance of the patent for the self-metering cartridge, upon payment of the applicable patent issuance fees.
read more

CardioGenics Announces Appointment of New Director

MISSISSAUGA, Ontario - January 12, 2015 - CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as an independent director.
read more

CORRECTING AND REPLACING -- CardioGenics Announces $1.3 Million Private Placement to European Investors

MISSISSAUGA, Ontario - June 12, 2014 - Please replace the release with the following corrected version due to an incorrect date in the last paragraph of the release, which should read "… late July 2014" instead of "… late July 2013."
read more

CardioGenics Announces $1.3 Million Private Placement to European Investors

MISSISSAUGA, Ontario - June 12, 2014 - CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the QL Care™ analyzer, an ultra-sensitive immunoassay point-of-care analyzer, and other products targeting the In-Vitro Diagnostics testing market, today announced it has sold $1.3 million of its common stock in a private placement to European institutional and other investors. Closing of the transaction is subject to listing of the shares on the NewConnect Market of the Warsaw Stock Exchange. WDM acted as offering agent and leading financial advisor on the transaction.
read more

CardioGenics Announces Commencement of Beta-Site Testing

MISSISSAUGA, Ontario - August 21, 2013 - CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the QL Care™ analyzer, an ultra-sensitive immunoassay point-of-care analyzer, and other products targeting the In-Vitro-Diagnostics testing market, announced today that it has commenced beta-site testing of its QL Care™ Analyzer and first cardiovascular test, Troponin-I. The beta-site testing was commenced in two hospitals affiliated with Wayne State University.
read more

CardioGenics Announces Schedule for Beta-Site Testing

MISSISSAUGA, Ontario - July 10, 2013 - CardioGenics Holdings Inc. (OTCBB:CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay Point-Of-Care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that beta-site testing of its QL Care™ Analyzer and Troponin-I test is scheduled to commence at hospitals affiliated with Wayne State University during the month of July 2013. The Company expects this testing program to be completed within 8-12 weeks.
read more

CardioGenics Announces Internal Review Board Approval for Beta-Site Testing

MISSISSAUGA, Ontario - June 05, 2013 - CardioGenics Holdings Inc. (OTCBB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay Point-Of-Care Analyzer, and other products targeting the In-Vitro-Diagnostics testing market, announced today that it has received approval of its clinical testing protocol from the Institutional Review Board of Wayne State University ("IRB"), which approval now enables the Company to commence beta-site testing of its QL Care™ Analyzer and first cardiovascular test, Troponin-I.
read more

CardioGenics Announces Agreements with INO to Manufacture QL Care™ Analyzers

MISSISSAUGA, Ontario - April 03, 2012 - CardioGenics Holdings Inc. (OTCBB: CGNH), developer of the ultra-sensitive QL Care™ analyzer, an immunoassay Point-Of-Care analyzer, and other products targeting the In-Vitro-Diagnostics testing market, announced today that it has entered into agreements with INO, a leading technology designer and developer based in Quebec, Canada, to manufacture the Company's QL Care™ Analyzer.
read more

CardioGenics Announces Filings and Listing Update

MISSISSAUGA, Ontario - March 23, 2012 - CardioGenics Holdings Inc. (OTCBB: CGNHE), a leading in vitro diagnostics company focused on developing products for the point-of-care (POC) segment of the market, today provided an update on its recent SEC filing and the subsequent change in its listing status on the OTCBB.
read more

CardioGenics Announces 2011 Financial Results

MISSISSAUGA, Ontario - January 31, 2012 - CardioGenics Holdings Inc. (OTCBB: CGNH), a leading in vitro diagnostics company focused on cardiology for the point-of-care (POC) market, today announced financial results and achievements for the year ended October 31, 2011.
read more

CardioGenics Announces Submission to IRB for Beta Site Protocol Approval

MISSISSAUGA, Ontario - December 20, 2011 - CardioGenics Holdings Inc. (OTCBB: CGNH), a leading In Vitro diagnostics company focused on cardiovascular testing products for the POC market, announced today that its application for Institutional Review Board (IRB) approval of its beta site testing protocol for the Company's QL Care™ Analyzer and Troponin-I cardiovascular test has been submitted.
read more

CardioGenics to Host Online Investor Presentation

MISSISSAUGA, Ontario - October 24, 2011 - CardioGenics Holdings Inc. (OTCBB: CGNH) announced today that it will host an online investor presentation regarding the status of its magnetic beads business, which is operated through the company’s Luxspheres subsidiary.
read more go to the presentationgo to the video

CardioGenics Commences Delivery of Beads to Merck Chimie for Select Customer Testing

MISSISSAUGA, Ontario - October 11, 2011 - CardioGenics Holdings Inc. (OTCBB: CGNH) announced today that commercial lots of its proprietary SAVAsphere^TM magnetic beads have been shipped from its Luxspheres subsidiary to its distributor, Merck Chimie, who will be shipping the beads to select customers for testing. The Company's proprietary microspheres technology and SAVAsphere magnetic beads have been developed to provide superior performance in diagnostic immunoassays.
read more

CardioGenics Retains Leading Investor Relations Firm

MISSISSAUGA, Ontario - October 06, 2011 - CardioGenics Holdings Inc. (OTCBB: CGNH) announced today that it has retained The Equicom Group Inc. (Equicom) to provide investor relations services in North America.
read more

Merck Chimie to Deliver CardioGenics Beads to Select Customers for Testing

MISSISSAUGA, Ontario - August 03, 2011 - CardioGenics Holdings Inc. (OTCBB: CGNH) announced today that Merck Chimie has informed the Company that it intends to begin shipping commercial lots of CardioGenics' proprietary magnetic beads (with CardioGenics' proprietary encapsulation) to select Merck Chimie customers on or about September 30, 2011.
read more

CardioGenics Holdings Inc. to Present Live, Online at RetailInvestorConferences.com on July 12th

NEW YORK and MISSISSAUGA, Ontario - July 11, 2011 - CardioGenics Holdings Inc. (CGNH.OB) announced today that Dr. Yahia Gawad, MB, Ch.B., MD, MSc., Director and CEO of CardioGenics, will be presenting at RetailInvestorConferences.com.
read more

USPTO Issues Patent for CardioGenics' Signal Amplification Technology

MISSISSAUGA, Ontario - June 29, 2011 - CardioGenics Holdings Inc. (CGNH.OB) announced today that the United States Patent & Trademark Office (USPTO) has notified the company that its patent application has been granted (issued patent # 7,964,415). This patent covers CardioGenics Inc.'s proprietary signal amplification technology, which is a key component of the core technology for CardioGenics' Ultra-Sensitive QL Care™ Analyzer. CardioGenics' unique methodology for signal amplification enables a decrease in the amount of binding reagents used in immunoassay diagnostic tests, such as those to be performed on the QL Care™ Analyzer, which, in turn, results in improved signal-to-noise ratio thereby increasing testing sensitivity.
read more

Luxspheres to Focus on the Further Development and Marketing of CardioGenics' SAVAsphere™ Magnetic Beads

MISSISSAUGA, Ontario - June 22, 2011 - CardioGenics Holdings Inc. (CGNH.OB) announced today the transfer of its magnetic beads business unit, which develops ultra sensitive magnetic beads for use in diagnostic devices, into its Canadian subsidiary, Luxspheres Inc. The beads business unit, which was previously operated out of the Company's CardioGenics Inc. Canadian subsidiary ("CardioGenics"), will now be operated exclusively out of Luxspheres, while CardioGenics concentrates on development and marketing of the its QL Care™ Analyzer.
read more go to the LuXSpheres website

CardioGenics to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc.

MISSISSAUGA, Ontario - May 23, 2011 - CardioGenics Holdings Inc. (CGNH: OTCB) announced today that Dr. Yahia Gawad, CEO of CardioGenics will be presenting at the 7th Annual Spring Growth Stock Conference hosted by Security Research Associates, Inc. The conference will be held on Tuesday, May 24th at the Omni Hotel in San Francisco.
read more go to the presentation

CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires

MISSISSAUGA, Ontario - March 08, 2011 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) announced today that it is making available to its common stockholders and Series 2 Class B common stockholders a "Stockholder Questionnaire," which the Company hopes will assist it in obtaining an accurate share count of the Company's shares currently held in "street name" through brokers, banks or other nominees.
read more go to questionnaire

Patent Applications Approved in Canada, the European Union & Japan

MISSISSAUGA, Ontario - February 22, 2011 - CardioGenics Holdings Inc. (CGNH.OB) announced today that it has been notified by the Canadian Intellectual Property Office that its patent application for the "core technology" utilized in its ultra-sensitive point-of-care immuno-analyzer, the QL Care™ Analyzer, has been granted. Patents covering the "core technology" have now been issued in Canada, the European Union and Japan. A patent application for the "core technology" is currently pending in the U.S. before the United States Patent & Trademark Office (USPTO).
read more

CardioGenics Expects to Go Head-to-Head with Analyzer Manufactured by Siemens

MISSISSAUGA, Ontario - February 03, 2011 - CardioGenics Holdings Inc. (CGNH.OB) announced today final plans for testing of its QL Care™ (QLCA) Analyzer. The data that will be collected from the testing at 4 hospitals in North America will be used as a key component of the Company's 510K application with the United States Food and Drug Administration. The 510K application will allow the FDA to determine whether the QLCA is equivalent to another device that is currently approved by the FDA for commercialization. Upon approval of the application, CardioGenics will begin marketing the QLCA throughout the United States.
read more

CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS

MISSISSAUGA, Ontario - February 01, 2011 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) announced today that CardioGenics and Merck Chimie SAS continue the commercialization process of CardioGenics' magnetic beads. Merck recently notified CardioGenics that while it is refining its encapsulation of the CardioGenics beads, it will also test a batch of magnetic beads coated with CardioGenics' proprietary silver-coating and polymer encapsulation processes (the "CardioGenics Encapsulated Beads") with the aim of commercializing the CardioGenics Encapsulated Beads while Merck Chimie is finalizing its owns proprietary encapsulation of the CardioGenics beads.
read more

CardioGenics Raises $1.9 Million in Private Placement

Mississauga, Ontario, November 04, 2010 - CardioGenics Holdings Inc. (OTCBB: CGNH) announced today that it has completed a private placement under which it has raised $1,930,575. The shares issued in connection with the private placement do not have registration rights and are, therefore, subject to the rights and restrictions of Rule 144. Further, no warrants were issued in connection with the private placement.
read more

CardioGenics featured on cover of Medical Device & Diagnostic Industry magazine

Mississauga, Ontario, October 06, 2010 - Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTCBB: CGNH), has authored a cover story for this month's Medical Device & Diagnostic Industry Magazine (MD+DI) which addresses improvements in diagnostic times using point-of-care technology. In the article, titled "Improving Diagnosis Times with New Point-of-Care Technology," Dr. Gawad reviews the in-vitro diagnostics market and the growth of point-of-care testing.
read more

Zacks Reiterates 'Outperform' Rating for CardioGenics Holdings Inc.

Mississauga, Ontario, September 23, 2010 - Zacks Equity Research issued an update report on CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) with a six-month price target of $1.22 per shares and a reiteration of its 'Outperform' rating.
read more

Zacks Rates CardioGenics 'Outperform' With Six-Month Target of $1.22

Mississauga, Ontario, August 24, 2010 - Zacks Equity Research initiated research coverage on CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) with a six-month target price of $1.22 per share.
read more

CardioGenics Featured on Canada's Business News Network

Mississauga, Ontario, August 18, 2010 - Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, took part in an interview on Canada's Business News Network (BNN) on Monday, August 16th to discuss the market potential and technical advantages of the Company's paramagnetic beads and QL Care Analyzer™.
read more
watch video

CardioGenics Ships Biologics Beads to Merck

Mississauga, Ontario, August 12, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, said its CardioGenics Inc. subsidiary completed its first shipment of commercial product of beads linked to biological material to Merck Chimie S.A.S. for use by Merck's customers in the production of antibodies and biologic drugs. CardioGenics' propriety linking technology enables the beads to double the yields of antibody production processes.
read more

CardioGenics Holdings Inc. Enters into Agreement with Burrill LLC

Mississauga, Ontario, August 11, 2010 - CCardioGenics Holdings Inc. (OTCBB: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company has entered into an agreement with Burrill LLC, the life sciences merchant banking arm of Burrill & Company, pursuant to which Burrill will assist the Company in developing strategic partnerships including with respect to its QL Care Analyzer and its core proprietary microsphere technologies.
read more

Merck Set to Distribute CardioGenics Beads for Central Lab Diagnostic Analyzers

Mississauga, Ontario, August 3, 2010 - CardioGenics Holdings Inc. (OTCBB: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that CardioGenics Inc. and Merck Chimie S.A.S. have agreed on a plan to commercialize CardioGenics’ proprietary paramagnetic beads, with shipments to Merck-Chimie’s customers scheduled to start mid-September 2010.
read more

CardioGenics Holdings Inc. Receives New Ticker Symbol

Mississauga, Ontario, July 22, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company's ticker symbol has been changed back to "CGNH" and the Company's common stock began trading under that new symbol yesterday.
read more

CardioGenics And Merck In Second Product Agreement

Mississauga, Ontario, July 14, 2010 - CardioGenics Holdings Inc. (OTCBB: CGNHD), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company‘s subsidiary, CardioGenics Inc., has entered into an agreement with Merck Chimie S.A.S. to adopt its proprietary biological-linking technology to Merck-supplied magnetic beads designed to increase yields in antibody manufacturing.
read more

CardioGenics Holdings Inc. Announces Initial Members of Scientific Advisory Board

Mississauga, Ontario, June 29, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNHD), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that Professors Robert Roberts and William J. Kostuk are the first two members to join the Company's Scientific Advisory Board. Biographical information for Drs. Roberts and Kostuk is detailed below.
read more

CardioGenics Holdings Inc. Receives New Ticker Symbol as a Result of Reverse Stock Split (OTCBB: CGNHD)

Mississauga, Ontario, June 21, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced that the Company has been assigned a new ticker symbol by FINRA as a result of its recently announced share consolidation. The new ticker symbol is OTCBB: CGNHD and the Company has been informed by FINRA that its common stock will begin trading under that symbol commencing tomorrow the 22nd of June 2010 when the share consolidation becomes effective in the market. The "D" in the new ticker symbol will be removed by FINRA 20 business days after tomorrow.
read more

CardioGenics Selects Clinical Test Sites For Its High Speed Portable Blood Analyzer

Mississauga, Ontario, June 21, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced the selection of four sites for clinical testing of its patented QL Care™ Analyzer, a portable diagnostic platform designed to produce test results with central lab-like accuracy in 15 minutes using whole blood.
read more

New Corporate Profile Posted On CardioGenics' Website

Mississauga, Ontario, June 18, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced a new corporate profile is available at http://www.cardiogenics.com/ataglance/ataglance.pdf
read more

CardioGenics Announces Reverse Stock Split

Mississauga, Ontario, June 18, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, announced today that the Company has filed a Certificate of Change with the Secretary of State of Nevada, which implements a share consolidation of the Company's authorized and outstanding common stock on a ten (old) for one (new) basis.
read more

CardioGenics Spotlighted in May Issue of Medical Tourism Magazine

Mississauga, Ontario, May 28, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics (IVD) market, is spotlighted in the May issue of Medical Tourism Magazine in an article written by CardioGenics founder and CEO Yahia Gawad, MD.
read more

CardioGenics Announces Update Regarding Status of Merck Agreement

Mississauga, Ontario, May 27, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care™ Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics (IVD) market, announced today a further update regarding the status of its agreement with Merck Chimie S.A.S. ("Merck Chimie"), one of the largest manufacturers and distributors of magnetic beads for the diagnostics market.
read more

CardioGenics Announces Retention of Redington, Inc. to Provide Investor Relations Services for the Company

Mississauga, Ontario, May 20, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, has retained Redington, Inc. to provide investor relations and financial communications services for the Company.
read more

CardioGenics to be Spotlighted in Three Publications During Month of April

Mississauga, Ontario, April 22, 2010 - CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, will be spotlighted in three publications during the month of April: Today's Medical Developments, Medical Design Technology and The Wall Street Transcript
read more

CardioGenics Announces Lock-Up Agreements with Board Members, Executives and Certain Other Stockholders

Mississauga, Ontario, March 25, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the Point-Of-Care (POC) segment of the IVD market announced today that the Company has entered into lock-up agreements with its directors (other than Dr. Yahia Gawad who previously entered into a lock-up agreement with the Company) pursuant to which the directors agreed to lock-up 38,759,113 shares of the Company's common stock held directly and indirectly by the directors through "Exchangeable Shares" in the Company's wholly-owned Ontario, Canada subsidiary, CardioGenics ExchangeCo Inc. ("ExchangeCo"). ExchangeCo and WeirFoulds LLP (as "trustee" under that certain Voting and Exchange Trust Agreement dated July 6, 2009 among the Company, ExchangeCo and WeirFoulds LLP) are also parties to these lock-up agreements.
read more

CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad

Mississauga, Ontario, March 16, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the Point-Of-Care (POC) segment of the IVD market announced today that the Company has entered into a lock-up agreement with its chief executive officer, Dr. Yahia Gawad, pursuant to which Dr. Gawad has agreed to lock-up 150,000,000 million shares of the Company's common stock held indirectly by Dr. Gawad through "Exchangeable Shares" in the Company's wholly-owned Ontario, Canada subsidiary, CardioGenics ExchangeCo Inc. ("ExchangeCo"). ExchangeCo and WeirFoulds LLP, as "trustee" under that certain Voting and Exchange Trust Agreement dated July 6, 2009 among the Company, ExchangeCo and WeirFoulds LLP, are also parties to the lock-up agreement.
read more

CardioGenics Announces Further Update Regarding Status of Merck Agreement

Mississauga, Ontario, March 10, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market,announced today a further update regarding the status of its agreement with Merck Chimie s.a.s. ("Merck Chimie").
read more

CardioGenics Holdings Inc. Announces Completion of Cartridge Design for QL Care Analyzer

Mississauga, Ontario, January 27, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market, announced today that it has completed the design of the self-metering cartridge for its POC diagnostic device, the QL Care Analyzer.The company has also filed a patent application regarding the self-metering cartridge.
read more

CardioGenics Announces Retention of Wolfe Axelrod Weinberger Associates LLC to Provide Investor Relations Services for the Company

Mississauga, Ontario, January 20, 2010 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, has retained Wolfe Axelrod Weinberger Associates LLC to provide investor relations services for the Company. Effective January 18, 2010, all shareholder inquires should be directed to: Wolfe Axelrod Weinberger Associates LLC Tel: 1.212.370.4500 E-Mail: rob@wolfeaxelrod.com
read more

Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive

Mississauga, Ontario, December 30, 2009 - Dr. Yahia Gawad, Chief Executive Officer of CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, was interviewed in MedTech Executive. The article touches on the technical and market environment for developing its QL Care Analyzer device, the FDA approval process, InVitro Diagnostic (IVD) trends, and the investment climate for immunoassay products following CardioGenics' recent business agreement with Merck Chimie, S.A.S. To read the article in full, please visit http://www.devicelink.com/mx/issuesupdate/09/12/gawad.html
read more

CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads

Mississauga, Ontario, November 24,2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, reports that Merck Chimie S.A.S. ("Merck Chimie") is progressing to the next phase of the commercialization of CardioGenics' proprietary silver coated paramagnetic Beads ("Beads").
read more

CardioGenics Holdings Inc. Featured in Medical Device Daily

Mississauga, Ontario, November 13, 2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, was featured in Medical Device Daily's November 12, 2009 edition.
read more

CardioGenics Holdings Inc. Announces Letter To Shareholders

Mississauga, Ontario, October 27, 2009 - CardioGenics Holdings Inc. (OTCBB: CGNH), a developer of technology and products targeting the immunoassay segment of the In-Vitro Diagnostic (IVD) testing market, has issued a letter to its shareholders. To view the letter in its entirety, please visit the following link: http://irgnews.com/node/1633.
read more

CardioGenics Holdings Inc. Announces Name, Ticker Symbol and CUSIP Number Change.

Mississauga, Ontario, October 26, 2009 - CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has received notification from FINRA that the name and ticker symbol change for the Company on the OTCBB will take place at the beginning of business on Tuesday, October 27, 2009.
read more

Company Name Changed to CardioGenics Holdings Inc.

Mississauga, Ontario, October 2, 2009 - JAG Media Holdings, Inc. (OTCBB: JAGH) filed with the Secretary of State of Nevada yesterday a certificate of amendment to its Articles of Incorporation, which changed the Company's name to CardioGenics Holdings Inc., to better reflect its new business direction following its acquisition of CardioGenics Inc., and increased the Company's authorized common shares from 500,000,000 to 650,000,000.
read more

JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc.

Mississauga, Ontario, September 11, 2009 - JAG Media Holdings, Inc. (OTC Bulletin Board: JAGH) has entered into an agreement with The Investor Relations Group, Inc. ("IRG"), pursuant to which IRG will provide various investor relations and public relations services for the Company in accordance with the terms of the agreement. As of Tuesday, September 15th, all stockholders should address any inquiries directly to IRG.
read more